HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
Kara D. Meister(Lucile Packard Children's Hospital), Umamaheswar Duvvuri(City University of New York), Matthew L. Hedberg(Carnegie Mellon University), Diego Alvarado(Unknown), Carolyn Kemp(University of Pittsburgh Medical Center), Theresa LaVallee(Achillion Pharmaceuticals (United States)), Jennifer R. Grandis(University of California, San Francisco), Seungwon Kim(UPMC Hillman Cancer Center), Nayel Khan(University of Pittsburgh Medical Center), Sucheta Kulkarni(University of Pittsburgh Medical Center), Neal R. Godse(University of Pittsburgh Medical Center)
Cited by 19
Related Papers
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590
Characterization of HPV and host genome interactions in primary head and neck cancers
|Proceedings of the National Academy of Sciences|2014|401